Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
Daxor (DXR) announces its participation in the MedAxiom CV Transforum Spring'25 Conference in Orlando, FL from April 24-26, 2025. The event will feature a presentation by WellStar Health System's Dr. Brian Howard, highlighting their successful implementation of blood volume analysis (BVA) technology in reducing acute kidney injury rates following left ventricular assist device implantation.
The company's BVA-guided care has demonstrated significant improvements in patient outcomes according to peer-reviewed studies, including:
- 82% reduction in 30-day mortality
- 86% reduction in 1-year mortality
- 56% reduction in 30-day readmissions
- 55% reduction in length of stay when performed on admission
Daxor's BVA technology provides 98% accurate data for optimizing treatment plans and individualizing patient care, leading to improved outcomes and reduced care costs.
Daxor (DXR) annuncia la sua partecipazione alla conferenza MedAxiom CV Transforum Spring'25 che si terrà a Orlando, FL, dal 24 al 26 aprile 2025. L'evento includerà una presentazione del Dr. Brian Howard del WellStar Health System, che illustrerà il loro successo nell'implementazione della tecnologia di analisi del volume sanguigno (BVA) per ridurre i tassi di insufficienza renale acuta dopo l'impianto di dispositivi di assistenza ventricolare sinistra.
Le cure guidate dalla tecnologia BVA dell'azienda hanno mostrato miglioramenti significativi negli esiti clinici, come evidenziato da studi peer-reviewed, tra cui:
- riduzione dell'82% della mortalità a 30 giorni
- riduzione dell'86% della mortalità a 1 anno
- riduzione del 56% delle riammissioni entro 30 giorni
- riduzione del 55% della durata della degenza quando eseguita al momento del ricovero
La tecnologia BVA di Daxor fornisce dati con una precisione del 98% per ottimizzare i piani di trattamento e personalizzare l'assistenza ai pazienti, migliorando i risultati e riducendo i costi delle cure.
Daxor (DXR) anuncia su participación en la conferencia MedAxiom CV Transforum Spring'25 que se celebrará en Orlando, FL, del 24 al 26 de abril de 2025. El evento contará con una presentación del Dr. Brian Howard del WellStar Health System, quien destacará la exitosa implementación de la tecnología de análisis de volumen sanguíneo (BVA) para reducir las tasas de lesión renal aguda tras la implantación del dispositivo de asistencia ventricular izquierda.
El cuidado guiado por la tecnología BVA de la compañía ha demostrado mejoras significativas en los resultados de los pacientes según estudios revisados por pares, incluyendo:
- reducción del 82% en la mortalidad a 30 días
- reducción del 86% en la mortalidad a 1 año
- reducción del 56% en las readmisiones a 30 días
- reducción del 55% en la duración de la estancia hospitalaria cuando se realiza al ingreso
La tecnología BVA de Daxor ofrece datos con un 98% de precisión para optimizar los planes de tratamiento y personalizar la atención al paciente, lo que conduce a mejores resultados y a una reducción de los costos de atención.
Daxor (DXR)는 2025년 4월 24일부터 26일까지 플로리다주 올랜도에서 열리는 MedAxiom CV Transforum Spring'25 컨퍼런스에 참여한다고 발표했습니다. 이번 행사에서는 WellStar Health System의 Brian Howard 박사가 좌심실 보조장치 이식 후 급성 신손상 발생률 감소를 위한 혈액량 분석(BVA) 기술의 성공적인 도입 사례를 발표할 예정입니다.
회사의 BVA 기반 치료는 동료 심사 논문들에 따르면 환자 결과에 큰 개선을 보여주었으며, 주요 내용은 다음과 같습니다:
- 30일 사망률 82% 감소
- 1년 사망률 86% 감소
- 30일 재입원율 56% 감소
- 입원 시 시행 시 입원 기간 55% 감소
Daxor의 BVA 기술은 치료 계획 최적화와 환자 맞춤형 치료를 위해 98%의 정확한 데이터를 제공하여 치료 결과 개선과 비용 절감을 가능하게 합니다.
Daxor (DXR) annonce sa participation à la conférence MedAxiom CV Transforum Spring'25 qui se tiendra à Orlando, FL, du 24 au 26 avril 2025. L'événement comprendra une présentation du Dr Brian Howard du WellStar Health System, mettant en lumière leur mise en œuvre réussie de la technologie d'analyse du volume sanguin (BVA) pour réduire les taux d'insuffisance rénale aiguë après l'implantation d'un dispositif d'assistance ventriculaire gauche.
Les soins guidés par la technologie BVA de l'entreprise ont démontré des améliorations significatives des résultats cliniques selon des études évaluées par des pairs, notamment :
- réduction de 82 % de la mortalité à 30 jours
- réduction de 86 % de la mortalité à 1 an
- réduction de 56 % des réadmissions à 30 jours
- réduction de 55 % de la durée d'hospitalisation lorsqu'elle est réalisée à l'admission
La technologie BVA de Daxor fournit des données avec une précision de 98 % pour optimiser les plans de traitement et individualiser les soins aux patients, conduisant à de meilleurs résultats et à une réduction des coûts de prise en charge.
Daxor (DXR) gibt seine Teilnahme an der MedAxiom CV Transforum Spring'25 Konferenz in Orlando, FL, vom 24. bis 26. April 2025 bekannt. Bei der Veranstaltung wird Dr. Brian Howard vom WellStar Health System eine Präsentation halten, in der die erfolgreiche Implementierung der Blutvolumenanalyse (BVA)-Technologie zur Verringerung der akuten Nierenschädigungsrate nach der Implantation eines linksventrikulären Assistenzsystems vorgestellt wird.
Die von der Firma geführte BVA-basierte Versorgung hat laut begutachteten Studien signifikante Verbesserungen der Patientenergebnisse gezeigt, darunter:
- 82% Reduktion der 30-Tage-Mortalität
- 86% Reduktion der 1-Jahres-Mortalität
- 56% Reduktion der Wiedereinweisungen innerhalb von 30 Tagen
- 55% Reduktion der Aufenthaltsdauer bei Durchführung bei Aufnahme
Die BVA-Technologie von Daxor liefert mit 98% Genauigkeit Daten zur Optimierung von Behandlungsplänen und individuellen Patientenbetreuung, was zu besseren Ergebnissen und geringeren Behandlungskosten führt.
- BVA technology demonstrates 98% accuracy in clinical applications
- Significant clinical outcomes: 82% reduction in 30-day mortality and 86% in 1-year mortality
- Proven 56% reduction in 30-day readmissions and 55% reduction in length of stay
- Technology successfully reduces acute kidney injury rates in LVAD implantation cases
- None.
WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation
Oak Ridge, TN, April 17, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’25 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 24-26, 2025. The Cardiovascular Transforum conference unites cardiovascular thought leaders from across the country to transform cardiovascular care together with leading industry innovators.
Wellstar Health System's Dr. Brian Howard will present findings showing how their Advanced Heart Failure program successfully reduced acute kidney injury rates following left ventricular assist device implantation through a multi-tiered approach centered on blood volume analysis (BVA). The presentation will share results from their retrospective cohort study and provide implementation strategies for attendees to replicate in their own programs.
“We’re honored to have expert clinicians share their firsthand experience with BVA—why it matters, how to effectively integrate it into heart failure programs, and the meaningful impact it has on patient outcomes and quality of life,” said Michael Feldschuh, CEO and President of Daxor.
BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
About MedAxiom
MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data, and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience. For additional information, visit MedAxiom.com.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What clinical benefits has Daxor's BVA technology demonstrated in patient outcomes?
How accurate is Daxor's Blood Volume Analysis (BVA) technology?
What will be presented at the MedAxiom CV Transforum Spring'25 regarding DXR's technology?
When and where is Daxor (DXR) presenting at the MedAxiom Cardiovascular Conference 2025?
